The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually […]readmore
Tags : ASCO20
Shots: The two companies divulged the results of ongoing P-II DESTINY-CRC01 study assessing Enhertu in patients with HER2+ unresectable and/or m-colorectal cancer, prior treated with 2L standard therapies. Results: ORR […]readmore
Shots: The P-II OPTIC study involves assessing three initial doses of Iclusig (15/30/45 mg) in 283 patients with CML in CF, or who had documented history of the presence of […]readmore
Biotech
Clinical Trials
Merck’s Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for
Shots: The P-III KEYNOTE-177 study involves assessing of Keytruda (200mg IV on Day 1 of each 3wks. cycle for up to 35cycles) vs SOC CT (mFOLFOX6 or FOLFIRI, with/ out […]readmore
Shots: The P-II study involves assessing of Bavencio in 15 women (median age 34yrs.) with GTT that are resistant to mono-CT. All patients had progressed on treatment with MTX; one […]readmore
Shots: HER2CLIMB study involves assessing of Tukysa (tucatinib) + trastuzumab + capecitabine vs trastuzumab + capecitabine alone in 612 patients in a ratio (2:1) with LA unresectable/m-HER2+ BC prior treated […]readmore
Shots: The CodeBreaK 100 development program evaluates AMG 510 (proposed INN sotorasib, qd) in heavily pretreated patients with a range of KRAS G12C-mutant solid tumors. Eligible patients were heavily pretreated […]readmore